Nexalin Technology, Inc. CEO Mark White issued a letter to shareholders on January 14, 2025, providing an update on the company's recent milestones and outlook for 2025. The letter highlighted advancements in its patented Deep Intracranial Frequency Stimulation (DIFS) technology for neurological and mental health conditions.
Key achievements noted include a 65% response rate in completed depression trials and promising results from Alzheimer’s research, which showed increased brain activity. The company also emphasized the successful development of its virtual clinic, poised to revolutionize mental health care with AI integration.
For 2025, Nexalin is pursuing CE Mark certification to expand into European markets and maintaining a strategic focus on PTSD, TBI, and addiction research for veterans. The company continues to leverage global approvals already secured in China, Brazil, and Oman, positioning itself in the growing neuromodulation market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.